Our road is paved with more than good intentions. Since our inception in 1998, the Alzheimer’s Drug Discovery Foundation (ADDF) and its affiliate, the Institute for the Study of Aging (ISOA), have contributed in significant and measurable ways to the progress toward conquering Alzheimer’s disease, related dementias and cognitive aging. With your help, we can do even more to advance worthy projects awaiting funding.
A 2008 progress report, The ISOA/ADDF Pipeline Project, catalogues our investments in biomedical research from our founding in 1998 to the end of 2006. Highlights from the report:
- Of the 94 drug discovery programs reported for the Pipeline report; 38 advanced at least 2 key stages in the drug development process
- Of the 94 reported programs funded, 56% secured new intellectual property, 17% have generated licenses, and investigators have applied for or been granted intellectual property rights covering several patent families
- An increasing ratio over time of progressive forward movement through the stages of drug discovery for each dollar invested
- Funded investigators have published hundreds of peer-reviewed articles
- Funded programs attracted hundreds of millions of dollars in follow-on funding from government grants to IPOs
A complete copy of The ISOA/ADDF Pipeline Project can be downloaded here.